Cancer Advisor

Immune Checkpoint Inhibitors (ICIs)—such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies—have revolutionized oncology by releasing the molecular "brakes" on cytotoxic T-cells. However, a major clinical challenge remains: only 20% to 40% of cancer patients achieve long-term durability or complete response when treated with monotherapy. The primary barrier to response is primary or acquired resistance, driven by an immunosuppressive tumor microenvironment (TME), cold tumor phenotypes, and impaired antigen presentation. Pioneering work by researchers and authors like Dr. Justus R. Hope highlights a powerful strategy: re-sensitizing tumors to immunotherapy using low-cost, synergistic adjuncts—specifically targeted diet, repurposed medications, and natural bioactive compounds. Table of Contents 1. Tuning Up Immunotherapy with Diet & the Gut Microbiome 2. The Top 7 Repurposed Drugs in Immunotherapy Synergy 3. Most Powerful Natural Immune Boosters...